[go: up one dir, main page]

EA201300102A1 - Лиофилизированная антигенная композиция - Google Patents

Лиофилизированная антигенная композиция

Info

Publication number
EA201300102A1
EA201300102A1 EA201300102A EA201300102A EA201300102A1 EA 201300102 A1 EA201300102 A1 EA 201300102A1 EA 201300102 A EA201300102 A EA 201300102A EA 201300102 A EA201300102 A EA 201300102A EA 201300102 A1 EA201300102 A1 EA 201300102A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
lyophilising
antigen composition
antigen
lyophilized
Prior art date
Application number
EA201300102A
Other languages
English (en)
Inventor
Доминик Ингрид Лемуан
Original Assignee
Глаксосмитклайн Байолоджикалс С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2007/055037 external-priority patent/WO2007137986A2/en
Priority claimed from GB0723044A external-priority patent/GB0723044D0/en
Priority claimed from GB0723900A external-priority patent/GB0723900D0/en
Application filed by Глаксосмитклайн Байолоджикалс С.А. filed Critical Глаксосмитклайн Байолоджикалс С.А.
Publication of EA201300102A1 publication Critical patent/EA201300102A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001152—Transcription factors, e.g. SOX or c-MYC
    • A61K39/001153—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

В настоящем изобретении предложены лиофилизированные композиции, содержащие антиген и агонист Толл-подобного рецептора (TLR) 9. Такие композиции можно разводить носителем, выбранным из группы носителей в форме частиц, состоящей из липосом, минеральных солей, эмульсий, полимеров и иммуностимулирующих комплексов (ISCOM), с получением иммуногенных композиций для применения в вакцинации. Здесь также предложены способы изготовления иммуногенных композиций из лиофилизированных композиций по изобретению и их применение в иммунизации.
EA201300102A 2007-05-24 2008-05-22 Лиофилизированная антигенная композиция EA201300102A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2007/055037 WO2007137986A2 (en) 2006-05-26 2007-05-24 Vaccination against cancer
GB0723044A GB0723044D0 (en) 2007-11-23 2007-11-23 Lyophillised antigen composition
GB0723900A GB0723900D0 (en) 2007-12-06 2007-12-06 Lyophillised antigen composition

Publications (1)

Publication Number Publication Date
EA201300102A1 true EA201300102A1 (ru) 2014-02-28

Family

ID=39714209

Family Applications (3)

Application Number Title Priority Date Filing Date
EA200901434A EA018201B1 (ru) 2007-05-24 2008-05-22 Лиофилизированная антигенная композиция
EA201300102A EA201300102A1 (ru) 2007-05-24 2008-05-22 Лиофилизированная антигенная композиция
EA201300101A EA201300101A1 (ru) 2007-05-24 2008-05-22 Лиофилизированная антигенная композиция

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA200901434A EA018201B1 (ru) 2007-05-24 2008-05-22 Лиофилизированная антигенная композиция

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201300101A EA201300101A1 (ru) 2007-05-24 2008-05-22 Лиофилизированная антигенная композиция

Country Status (23)

Country Link
US (2) US20090035360A1 (ru)
EP (3) EP2476431A1 (ru)
JP (1) JP5331105B2 (ru)
KR (2) KR20110091817A (ru)
CN (1) CN101678091A (ru)
AR (1) AR066676A1 (ru)
AU (1) AU2008252911B2 (ru)
BR (1) BRPI0811228A2 (ru)
CA (1) CA2687632C (ru)
CL (1) CL2008001491A1 (ru)
CY (1) CY1113446T1 (ru)
DK (1) DK2148697T3 (ru)
EA (3) EA018201B1 (ru)
ES (1) ES2395333T3 (ru)
HR (1) HRP20121019T1 (ru)
MX (1) MX2009012381A (ru)
PE (1) PE20090281A1 (ru)
PL (1) PL2148697T3 (ru)
PT (1) PT2148697E (ru)
SI (1) SI2148697T1 (ru)
TW (1) TW200911304A (ru)
UY (1) UY31101A1 (ru)
WO (1) WO2008142133A1 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006235507B2 (en) 2005-04-12 2012-08-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
CA2626238C (en) 2005-10-17 2015-10-06 Sloan Kettering Institute For Cancer Research Wt1 hla class ii-binding peptides and compositions and methods comprising same
PL2010209T3 (pl) 2006-04-10 2017-04-28 Sloan Kettering Inst For Cancer Res Immunogeniczne peptydy WT-1 i sposoby ich użycia
WO2008127651A1 (en) * 2007-04-13 2008-10-23 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
JP2013505201A (ja) * 2009-04-03 2013-02-14 デューク ユニバーシティー 広域反応性中和抗ｈｉｖ抗体を誘導するための配合物
GB0910045D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
GB0910046D0 (en) * 2009-06-10 2009-07-22 Glaxosmithkline Biolog Sa Novel compositions
CN103249431B (zh) 2010-12-14 2016-11-02 葛兰素史密丝克莱恩生物有限公司 分枝杆菌抗原组合物
JP2014529338A (ja) * 2011-07-22 2014-11-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｐｒａｍｅの精製
US20150104413A1 (en) 2012-01-13 2015-04-16 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof
DK2945647T3 (da) 2013-01-15 2020-11-16 Memorial Sloan Kettering Cancer Center Immunogene wt-1-peptider og anvendelsesmetoder deraf
US10815273B2 (en) 2013-01-15 2020-10-27 Memorial Sloan Kettering Cancer Center Immunogenic WT-1 peptides and methods of use thereof
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof
JP6741580B2 (ja) 2013-12-31 2020-08-19 インフェクシャス ディズィーズ リサーチ インスティチュート 単一バイアルのワクチン製剤
AU2014388299A1 (en) * 2014-03-25 2016-10-20 The Government Of The United States Of America As Represented By The Secretary Of The Army Methods for enhancing the immunostimulation potency of aluminum salt-adsorbed vaccines
CN112812143A (zh) 2015-11-06 2021-05-18 佐剂技术公司 三萜皂苷类似物
BR112019011286A2 (pt) 2016-12-07 2019-10-15 Glaxosmithkline Biologicals S.A. métodos para produzir uma composição de lipossoma, para preparar uma composição de vacina e para preparar um kit de vacina.
EP3697802A4 (en) 2017-10-16 2021-11-24 Adjuvance Technologies, Inc. TRITERPENIC SAPONIN ANALOGUES
WO2020016322A1 (en) 2018-07-19 2020-01-23 Glaxosmithkline Biologicals Sa Processes for preparing dried polysaccharides

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US666A (en) 1838-04-02 Sfbing-bock for coagh and railroad-gab
US5827A (en) 1848-10-03 Improved table-cutlery
US6222020B1 (en) * 1987-01-07 2001-04-24 Imperial Cancer Research Technology Limited Antigens derived from the core protein of the human mammary epithelial mucin
WO1988005054A1 (en) 1987-01-07 1988-07-14 Imperial Cancer Research Technology Limited Probe
US5057540A (en) * 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US4963484A (en) 1988-01-29 1990-10-16 Dana-Farber Cancer Institute, Inc. Genetically engineered polypeptides with determinants of the human DF3 breast carcinoma-associated antigen
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5256643A (en) 1990-05-29 1993-10-26 The Government Of The United States Human cripto protein
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
US5744144A (en) 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
US5688506A (en) 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
ATE420171T1 (de) 1994-07-15 2009-01-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US5830753A (en) 1994-09-30 1998-11-03 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor dage and uses thereof.
US5981215A (en) 1995-06-06 1999-11-09 Human Genome Sciences, Inc. Human criptin growth factor
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US6130043A (en) 1997-05-02 2000-10-10 Abbott Laboratories Reagents and methods useful for detecting diseases of the prostate
CA2304599A1 (en) * 1997-09-25 1999-04-01 Sloan-Kettering Institute For Cancer Research Fucosyl gm1-klh conjugate vaccine against small cell lung cancer
GB9727262D0 (en) 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
EP1088072A2 (en) 1998-06-22 2001-04-04 Incyte Pharmaceuticals, Inc. Prostate cancer-associated genes
WO2000009159A1 (en) * 1998-08-10 2000-02-24 Aquila Biopharmaceuticals, Inc. Compositions of cpg and saponin adjuvants and methods thereof
US20030235557A1 (en) * 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
CN1201004C (zh) 1999-01-29 2005-05-11 考丽克萨有限公司 HER－2/neu融合蛋白
BR0008917A (pt) 1999-03-11 2002-01-15 Smithkline Beecham Biolog Compostos
US6949520B1 (en) * 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
SI1265915T1 (sl) 2000-02-23 2011-02-28 Glaxosmithkline Biolog Sa Nove spojine
US20040022814A1 (en) * 2000-06-15 2004-02-05 O'hagan Derek Microparticles with adsorbent surfaces, methods of making same, and uses thereof
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP2292632A3 (en) 2000-09-26 2012-07-25 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
US20030031684A1 (en) 2001-03-30 2003-02-13 Corixa Corporation Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
US7553494B2 (en) * 2001-08-24 2009-06-30 Corixa Corporation WT1 fusion proteins
HUP0402259A3 (en) 2001-09-20 2010-01-28 Glaxo Group Ltd Vaccines
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
GB0218821D0 (en) * 2002-08-13 2002-09-18 Glaxosmithkline Biolog Sa Novel compositions
AU2003297499A1 (en) * 2002-12-23 2004-07-22 City Of Hope Modified vaccinia ankara expressing p53 in cancer immunotherapy
GB0323968D0 (en) 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
EP1547581A1 (en) * 2003-12-23 2005-06-29 Vectron Therapeutics AG Liposomal vaccine for the treatment of human hematological malignancies
GB0409940D0 (en) * 2004-05-04 2004-06-09 Glaxosmithkline Biolog Sa Vaccine
GB0411411D0 (en) 2004-05-21 2004-06-23 Glaxosmithkline Biolog Sa Vaccines
JP2008502732A (ja) * 2004-06-12 2008-01-31 ファーマ パシフィック プロプリエタリイ リミテッド ワクチンに対する免疫応答を増強する方法
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
WO2006092017A1 (en) 2005-03-02 2006-09-08 Solbec Pharmaceuticals Limited Glycoalkaloid and tlr agonist combinations and various uses thereof
KR20080026181A (ko) * 2005-06-17 2008-03-24 맨카인드 코포레이션 암세포 및 종양 기질에 발현된 우성 및 준우성 에피토프에대한 다가 면역반응을 유발하기 위한 방법 및 조성물

Also Published As

Publication number Publication date
AU2008252911B2 (en) 2013-09-05
CA2687632C (en) 2013-01-15
MX2009012381A (es) 2009-12-01
EP2148697B1 (en) 2012-10-03
UY31101A1 (es) 2009-01-05
HRP20121019T1 (hr) 2013-01-31
KR20100017519A (ko) 2010-02-16
CA2687632A1 (en) 2008-11-27
KR101238795B1 (ko) 2013-03-07
US20090035360A1 (en) 2009-02-05
ES2395333T3 (es) 2013-02-12
EA200901434A1 (ru) 2010-06-30
EP2476431A1 (en) 2012-07-18
KR20110091817A (ko) 2011-08-12
CY1113446T1 (el) 2016-06-22
EP2148697A1 (en) 2010-02-03
JP5331105B2 (ja) 2013-10-30
BRPI0811228A2 (pt) 2014-10-21
TW200911304A (en) 2009-03-16
DK2148697T3 (da) 2012-12-17
US20110059163A1 (en) 2011-03-10
EA201300101A1 (ru) 2014-02-28
EP2489367A1 (en) 2012-08-22
PE20090281A1 (es) 2009-03-28
AR066676A1 (es) 2009-09-02
SI2148697T1 (sl) 2013-01-31
AU2008252911A1 (en) 2008-11-27
CN101678091A (zh) 2010-03-24
WO2008142133A1 (en) 2008-11-27
US8557247B2 (en) 2013-10-15
PT2148697E (pt) 2012-12-24
JP2010527964A (ja) 2010-08-19
PL2148697T3 (pl) 2013-02-28
EA018201B1 (ru) 2013-06-28
CL2008001491A1 (es) 2008-11-28

Similar Documents

Publication Publication Date Title
EA201300102A1 (ru) Лиофилизированная антигенная композиция
MX2013013111A (es) Composicion inmunogenica que presenta antigeno multiple, y metodos y usos de la misma.
MX2024010239A (es) Receptores de antigenos quimericos dirigidos a bcma y metodos de uso de estos.
LT2486938T (lt) Vakcinos kompozicija, turinti sintetinio adjuvanto
AR069495A1 (es) Construcciones de union de antigenos para el tratamiento de cancer o enfermedades inflamatorias (asma, artritis o artrosis)
EA201390630A1 (ru) Композиции микобактериальных антигенов
WO2010104749A3 (en) Antigen presenting cell targeted cancer vaccines
MX2011009438A (es) Anticuerpos anti-cd40 y usos de los mismos.
MX2023000192A (es) Particulas conjugadas con peptidos.
PH12015501284A1 (en) Bcma antigen binding proteins
EA201291105A1 (ru) Пероральная вакцина, содержащая антиген и агонист toll-подобного рецептора
PH12013500315A1 (en) Antibodies that bind myostatin, compositions and methods
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
EA201100268A1 (ru) Вакцина
EA201790757A1 (ru) Связывающие антиген cd27l белки
PH12014501410A1 (en) Compositions and methods for antibodies targeting factor p
TR201802380T4 (tr) Benzonaftiridin içeren aşılar.
EA201170636A1 (ru) Антагонисты толл-подобного рецептора 3
IN2014CN03454A (ru)
EA201390811A1 (ru) Пептиды tomm34 и содержащие их вакцины
MX344579B (es) Peptidos hjurp y vacunas que incluyen los mismos.
MX2012008761A (es) Adyuvante para la preparacion de composiciones de vacuna conceptualizadas para la prevencion de coccidiosis.
TH87147B (th) วัคซีนสำหรับการทำให้เกิดภูมิคุ้มกันที่ต้านเชื้อเฮลิโคแมคเตอร์
TN2013000064A1 (en) Antibodies that bind myostatin, compositions and methods